Twist Bioscience (TWST) SEC Filings, Aug-Sep 2025

Form 144 filed for Twist Bioscience (TWST) reports a proposed sale of 2,265 common shares through Fidelity Brokerage Services with an aggregate market value of $58,346.17 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired on 09/05/2025 through restricted stock vesting from the issuer and payment was recorded as compensation. The filer has sold 10,455 common shares in the past three months across four transactions (06/20/2025: 1,678; 07/02/2025: 476; 08/04/2025: 5,585; 08/21/2025: 2,716) generating gross proceeds of $300,156.58. Outstanding shares listed are 60,360,925. The filer affirms no undisclosed material adverse information and the notice includes the statutory signature/representation language.

Form 144 notice from Robert Werner regarding Twist Bioscience (TWST)

The filing reports a proposed public sale of 235 shares of TWST common stock through Fidelity Brokerage Services with an approximate aggregate market value of $6,053.58, slated for 09/08/2025. Those 235 shares were acquired via restricted stock vesting on 09/05/2025 and paid as compensation. The filing lists TWST’s shares outstanding as 60,360,925. The filer also disclosed sales during the prior three months totaling 1,277 shares on 08/04, 08/21 and 08/25 with combined gross proceeds of $34,075.88. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

The filing is a Form 144 notice for Twist Bioscience Corporation (TWST) reporting a proposed sale of 892 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $22,977.83 and an approximate sale date of 09/08/2025. The shares were acquired on 09/05/2025 by restricted stock vesting and paid as compensation. The filer discloses four prior sales by the same person between 06/20/2025 and 08/21/2025, totaling 2,308 shares with combined gross proceeds shown. The notice includes the required statement that the seller is not aware of undisclosed material adverse information.

Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 853 shares of common stock on 08/25/2025 at a price of $27.691 per share to satisfy tax withholding obligations related to vested restricted stock units. After the transaction, Mr. Werner beneficially owned 48,689 shares directly. The Form 4 was executed by an attorney-in-fact and dated 08/27/2025.

This filing indicates a routine "sell-to-cover" transaction mandated by the issuer to meet tax obligations on vesting and does not represent a voluntary market sale by the reporting person. The disclosure follows Section 16 reporting requirements and shows continued ownership of a material stake by the reporting officer.

The Form 4 shows that Emily M. Leproust, Twist Bioscience Corp (TWST) CEO and director, reported a sale of 2,716 shares of TWST common stock on 08/21/2025 at $25.964 per share to satisfy tax-withholding obligations tied to vested restricted stock units; the filing states these were "sell to cover" transactions required by the issuer and not discretionary trades. After the transaction, Leproust beneficially owned 637,005 shares. The filing also discloses outstanding employee stock options with various exercise prices and exercisable/expiration details, including options exercisable immediately at $5.95, $8.82, $26.66 and $23.33 and a $67.85 option with 64,950 underlying shares exercisable through 08/31/2030.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 08/21/2025 to satisfy tax withholding on vesting restricted stock units. The Form 4 shows a sale of 238 shares at a price of $25.964 per share, leaving the reporting person with 49,542 shares beneficially owned after the transaction. The filing clarifies this was a mandatory "sell to cover" required by the issuer's equity incentive plan and not an independent trading decision by the reporting person.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of company stock on 08/21/2025. The Form 4 shows 619 shares were disposed of at a price of $25.964 per share as a sell-to-cover transaction to satisfy tax withholding on vested Restricted Stock Units. After the transaction the reporting person beneficially owned 125,729 shares, which the filing notes includes shares acquired under the company Employee Stock Purchase Plan that were exempt under Rule 16b-3. The form was signed by an attorney-in-fact on 08/25/2025.

Twist Bioscience Corp (TWST) reporting person Adam Laponis, Chief Financial Officer, filed a Form 4 disclosing a non-discretionary sale of 918 shares of common stock on 08/21/2025 at a reported price of $25.964 per share. The filing states these shares were sold to satisfy tax withholding obligations associated with the vesting of restricted stock units under the companys equity plans, described as a mandatory "sell to cover" and not a discretionary trade.

Following the transaction, the reporting person beneficially owns 102,917 shares, which includes shares purchased under the companys Employee Stock Purchase Plan as noted in the filing. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Laponis and contains explanatory notes clarifying the nature of the sale and the ESPP exemption.

Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), reported a non-discretionary sale of 1,840 shares of Twist common stock on 08/21/2025 at a price of $25.964 per share. The filing states these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units and were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 233,529 shares, which the filing notes includes shares acquired under the company’s Employee Stock Purchase Plan in an exempt transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Finn on 08/25/2025.